Quantinno Capital Management LP Takes $586,000 Position in Phreesia, Inc. $PHR

Quantinno Capital Management LP purchased a new stake in Phreesia, Inc. (NYSE:PHR) in the 1st quarter, HoldingsChannel reports. The firm purchased 69,879 shares of the company’s stock, valued at approximately $586,000.

A number of other hedge funds have also recently added to or reduced their stakes in PHR. Pale Fire Capital SE acquired a new stake in Phreesia in the first quarter valued at approximately $72,481,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Phreesia in the 1st quarter valued at $376,000. Inceptionr LLC acquired a new stake in shares of Phreesia in the 1st quarter valued at $88,000. Sei Investments Co. lifted its stake in shares of Phreesia by 20.7% in the 1st quarter. Sei Investments Co. now owns 137,622 shares of the company’s stock valued at $1,153,000 after purchasing an additional 23,560 shares during the last quarter. Finally, Globeflex Capital L P boosted its holdings in Phreesia by 124.0% in the first quarter. Globeflex Capital L P now owns 22,552 shares of the company’s stock worth $189,000 after purchasing an additional 12,482 shares in the last quarter. Institutional investors and hedge funds own 92.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on PHR shares. Barclays reissued an “equal weight” rating and set a $10.00 target price (down from $24.00) on shares of Phreesia in a research report on Thursday, May 14th. Wall Street Zen upgraded Phreesia from a “hold” rating to a “buy” rating in a research note on Saturday, May 30th. Wells Fargo & Company reissued an “equal weight” rating and set a $9.00 price objective (down from $15.00) on shares of Phreesia in a report on Wednesday, May 20th. Piper Sandler lowered Phreesia from an “overweight” rating to a “neutral” rating and set a $12.00 price objective on the stock. in a report on Thursday, May 28th. Finally, Citigroup reissued a “market perform” rating on shares of Phreesia in a research note on Friday, May 29th. Nine investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Phreesia has an average rating of “Hold” and an average price target of $16.65.

Phreesia Stock Up 4.8%

PHR stock opened at $11.99 on Thursday. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.76 and a quick ratio of 1.76. Phreesia, Inc. has a 52-week low of $7.77 and a 52-week high of $32.76. The company has a 50-day moving average of $10.66 and a two-hundred day moving average of $10.53. The stock has a market capitalization of $741.35 million, a price-to-earnings ratio of 79.96 and a beta of 0.85.

Phreesia (NYSE:PHR) last posted its quarterly earnings data on Wednesday, May 27th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.03. Phreesia had a return on equity of 5.13% and a net margin of 1.85%.The business had revenue of $130.94 million for the quarter, compared to analyst estimates of $130.08 million. During the same period in the previous year, the company posted ($0.07) earnings per share. The firm’s revenue for the quarter was up 12.9% on a year-over-year basis. As a group, equities research analysts anticipate that Phreesia, Inc. will post 0.39 EPS for the current year.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.